Impact of the new Beckman Coulter Cytomics FC 500 5-color flow cytometer on a regional flow cytometry clinical laboratory service

Laboratory Hematology

Volumn 10, Issue 2, 2004, Pages 102-108

  Luider, Joanne ^a   Cyfra, M ^a   Johnson, P ^a   Auer, I ^a  

^a CALGARY LABORATORY SERVICES   (Canada)

Author keywords

5 Color; Acute leukemia; Cytomics FC 500; Flow cytometry; Immunophenotyping; Interstitial lung disease; Lymphoma; Minimal residual disease; Productivity

Indexed keywords

ACUTE LEUKEMIA; ARTICLE; BLOOD DISEASE; CHRONIC LEUKEMIA; CLINICAL LABORATORY; COMPUTER; COMPUTER PROGRAM; CONTROLLED STUDY; COST CONTROL; DEVICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FLOW CYTOMETRY; IMMUNE DEFICIENCY; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; INTERSTITIAL LUNG DISEASE; LABORATORY DIAGNOSIS; LYMPHOMA; MINIMAL RESIDUAL DISEASE; NEUROBLASTOMA; QUALITY CONTROL; THROMBOCYTE ANOMALY;

AUTOMATION; CLINICAL LABORATORY INFORMATION SYSTEMS; COLOR; EFFICIENCY; EVALUATION STUDIES; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; LABORATORIES; LUNG DISEASES, INTERSTITIAL; LYMPHOPROLIFERATIVE DISORDERS; QUALITY CONTROL;

EID: 3042842907     PISSN: 10802924     EISSN: None     Source Type: Journal    
DOI: 10.1532/LH96.04121     Document Type: Article

References (21)

1. Cytomics FC 500 Manual. Fullerton, Calif: Beckman Coulter; April 2002.
2. Brown W, Kaplan S, Keeney M, Johnson K, Wolfe N, Chin Yee I. Workflow improvement with random access and enhanced flagging on the new Coulter LH 750 hematology analyzer. Lab Hematol. 2001;7:229-235.
3. McFadden S. Automating the review process to improve productivity in the hematology laboratory. Lab Hematol. 2002;8:225-229.
4. Markin RS, Whalen SA. Laboratory automation: trajectory, technology and tactics. Clin Chem. 2000;46:764-771.
5. Truchaud A, Le Neel T, Brochard H, Malvaux S, Moyon M, Cazaubiel M. New tools for laboratory design and management. Clin Chem. 1997;43:1709-1715.
6. Halasey S. The global market for diagnostics: new technologies, foreign lands. IVD Technol Mag. September 2002.
7. Mylotarg Package insert. http://www.wyeth.com/content/ShowLabeling.asp?id= 119. Accessed April 1, 2004.
8. Baer M, Stewart CC, Dodge RK, et al. High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection. Cancer and Leukemia Group B Study 8361. Blood. 2001;97:3574-3580.
9. Krampera M, Vitale A, Vincenzi C, et al. Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. Br J Haematol. 2003;120:74-79.
10. Dworzak MN, Froschl G, Printz D, et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood ALL. Blood. 2002;99:1952-1958.
11. Reinhardt D, Langebrake C, Creutzig U, et al. Minimal residual disease in AML in children-standardisation and evaluation of immunophenotyping in the AML-BFM-98 study [in German]. Klin Padiatr. 2002;214:179-187.
12. Borkhardt A, Wuchter C, Viehmann S, et al. Infant acute lymphoblastic leukemia - combined cytogenetic, immunophenotypical, and molecular analysis of 77 cases. Leukemia. 2002;16:1685-1690.
13. Matures E. New additions to antibody panels in the characterisation of chronic lymphoproliferative disorders [Review]. J Clin Path. 2002;55:180-183.
14. San-Miguel JF, Vidriales MB, Orfao A. Immunological evaluation of MRD in AML. Best Pract Res Clin Haematol. 2002;15: 105-118.
15. Maloum K, Sutton L, Bauder S, et al. Novel flow cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in CLL. Br J Haematol. 2002;119:970-975.
16. Sanchez ML, Orfao A, Vidriales B, et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific 4-color stainings to be used for minimal residual disease detection. Leukemia. 2002;16:1460-1469.
17. Kappelmayer J, Gratama JW, Orfao A, et al. Flow cytometric detection of intracellular myeloperoxidase, CD3 and CD79a. Interaction between monoclonal antibody clones, fluorochromes and sample preparation protocols. J Immunol Methods. 2000;242: 53-65.
18. Lima M, Almeida J, dos Anjos Teixeira M, Queiros ML, Justica B, Orfao A. The "ex vivo" patterns of CD2/CD7, CD57/CD11c, CD38/CD11b, CD45a/CD45o and CD11a/HLA-DR expression identify acute/early and chronic/late NK cell activation states. Blood Cells Mol Dis. 2002;28:181-190.
19. Braylan RC, Orfao A, Borowitz MJ, Davis BH. Optimal number of reagents required to evaluate heatolymphoid neoplasias: results of an international consensus meeting. Cytometry. 2001;46: 23-27.
20. Munoz L, Nomdedeu JF, Villamor N, et al. AML with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual disease. Leukemia. 2003;17:76-82.
21. Bjorklund E, Mazur J, Soderhall S, Porwit-MacDonald A. Flow cytometric follow up of minimal residual disease in bone marrow gives prognostic information in children with ALL. Leukemia. 2003;17:138-148.